Literature DB >> 20221857

The emerging role of the selective A2A agonist in pharmacologic stress testing.

Anthony S Gemignani1, Brian G Abbott.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20221857     DOI： 10.1007/s12350-010-9211-9

Source DB:  PubMed          Journal:  J Nucl Cardiol        ISSN： 1071-3581            Impact factor:   5.952


× No keyword cloud information.
  17 in total

Review 1.  Pharmacologic stress myocardial perfusion imaging: a practical approach.

Authors:  Michael I Miyamoto; Sharon L Vernotico; Haresh Majmundar; Gregory S Thomas
Journal:  J Nucl Cardiol       Date:  2007-04       Impact factor: 5.952

2.  Regadenoson pharmacokinetics and tolerability in subjects with impaired renal function.

Authors:  Toufigh Gordi; Brent Blackburn; Hsiao Lieu
Journal:  J Clin Pharmacol       Date:  2007-07       Impact factor: 3.126

3.  Initial clinical experience with a selective A2A receptor agonist, regadenoson, in a patient with end-stage renal disease on hemodialysis.

Authors:  Saaron Laighold; Regina Druz
Journal:  J Nucl Cardiol       Date:  2009-01-22       Impact factor: 5.952

4.  Pharmacologic stress perfusion imaging with adenosine: role of simultaneous low-level treadmill exercise.

Authors:  Habib Samady; Frans J Th Wackers; Tammy M Joska; Barry L Zaret; Diwakar Jain
Journal:  J Nucl Cardiol       Date:  2002 Mar-Apr       Impact factor: 5.952

5.  Safety profile of adenosine stress perfusion imaging: results from the Adenoscan Multicenter Trial Registry.

Authors:  M D Cerqueira; M S Verani; M Schwaiger; J Heo; A S Iskandrian
Journal:  J Am Coll Cardiol       Date:  1994-02       Impact factor: 24.094

6.  Adenosine versus regadenoson comparative evaluation in myocardial perfusion imaging: results of the ADVANCE phase 3 multicenter international trial.

Authors:  Ami E Iskandrian; Timothy M Bateman; Luiz Belardinelli; Brent Blackburn; Manuel D Cerqueira; Robert C Hendel; Hsiao Lieu; John J Mahmarian; Ann Olmsted; S Richard Underwood; João Vitola; Whedy Wang
Journal:  J Nucl Cardiol       Date:  2007 Sep-Oct       Impact factor: 5.952

7.  Effects of age, gender, obesity, and diabetes on the efficacy and safety of the selective A2A agonist regadenoson versus adenosine in myocardial perfusion imaging integrated ADVANCE-MPI trial results.

Authors:  Manuel D Cerqueira; Patricia Nguyen; Peter Staehr; S Richard Underwood; Ami E Iskandrian
Journal:  JACC Cardiovasc Imaging       Date:  2008-05

8.  Safety of regadenoson, an adenosine A2A receptor agonist for myocardial perfusion imaging, in mild asthma and moderate asthma patients: a randomized, double-blind, placebo-controlled trial.

Authors:  Brian R Leaker; B O'Connor; Trevor T Hansel; Peter J Barnes; Lixen Meng; Vandana S Mathur; Hsiao D Lieu
Journal:  J Nucl Cardiol       Date:  2008-04-14       Impact factor: 5.952

9.  Safety of regadenoson, a selective adenosine A2A agonist, in patients with chronic obstructive pulmonary disease: A randomized, double-blind, placebo-controlled trial (RegCOPD trial).

Authors:  Gregory S Thomas; Bruce R Tammelin; George L Schiffman; Rudy Marquez; Deborah L Rice; Douglas Milikien; Vandana Mathur
Journal:  J Nucl Cardiol       Date:  2008-04-14       Impact factor: 5.952

10.  Safety of regadenoson in patients with end-stage renal disease.

Authors:  Wael Aljaroudi; Daniel Hermann; Fadi Hage; Jaekyeong Heo; Ami E Iskandrian
Journal:  Am J Cardiol       Date:  2009-11-18       Impact factor: 2.778
View more
  7 in total

Review 1.  Selective adenosine agonists and myocardial perfusion imaging.

Authors:  Gilbert J Zoghbi; Ami E Iskandrian
Journal:  J Nucl Cardiol       Date:  2012-02       Impact factor: 5.952

2.  Ischemic electrocardiogram during pharmacologic stress with regadenoson.

Authors:  Kamran Haleem; Brian Malm
Journal:  J Nucl Cardiol       Date:  2011-10       Impact factor: 5.952

Review 3.  New Trends in Radionuclide Myocardial Perfusion Imaging.

Authors:  Guang-Uei Hung; Yuh-Feng Wang; Hung-Yi Su; Te-Chun Hsieh; Chi-Lun Ko; Ruoh-Fang Yen
Journal:  Acta Cardiol Sin       Date:  2016-03       Impact factor: 2.672

4.  Aminophylline and caffeine for reversal of adverse symptoms associated with regadenoson SPECT MPI.

Authors:  Jesse A Doran; Waseem Sajjad; Marabel D Schneider; Rohit Gupta; Maria L Mackin; Ronald G Schwartz
Journal:  J Nucl Cardiol       Date:  2016-03-29       Impact factor: 5.952

Review 5.  Regadenoson use in patients with chronic obstructive pulmonary disease: the state of current knowledge.

Authors:  Yasmeen Golzar; Rami Doukky
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2014-01-22

6.  Adenosine A2A receptor agonist prevents cardiac remodeling and dysfunction in spontaneously hypertensive male rats after myocardial infarction.

Authors:  Jaqueline S da Silva; Daniele Gabriel-Costa; Roberto T Sudo; Hao Wang; Leanne Groban; Emanuele B Ferraz; José Hamilton M Nascimento; Carlos Alberto M Fraga; Eliezer J Barreiro; Gisele Zapata-Sudo
Journal:  Drug Des Devel Ther       Date:  2017-03-06       Impact factor: 4.162

7.  A delicate balance: CD73-generated adenosine limits the severity of graft vs. host disease but also constrains the allogeneic graft vs. tumor effect.

Authors:  Linda F Thompson; Hiroki Tsukamoto; Petya Chernogorova; Robert Zeiser
Journal:  Oncoimmunology       Date:  2013-01-01       Impact factor: 8.110
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.